EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update
(2017) In Annals of the Rheumatic Diseases 76(1). p.17-28- Abstract
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a... (More)
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal antiinflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
(Less)
- author
- organization
- publishing date
- 2017-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 76
- issue
- 1
- pages
- 17 - 28
- publisher
- BMJ Publishing Group
- external identifiers
-
- scopus:84991585385
- pmid:27697765
- wos:000392425200005
- ISSN
- 0003-4967
- DOI
- 10.1136/annrheumdis-2016-209775
- language
- English
- LU publication?
- yes
- id
- 58c284e2-143e-4ee8-87fe-3484a06f96ac
- date added to LUP
- 2016-11-16 10:17:23
- date last changed
- 2025-01-25 16:22:18
@article{58c284e2-143e-4ee8-87fe-3484a06f96ac,
abstract = {{<p>Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal antiinflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.</p>}},
author = {{Agca, R. and Heslinga, S. C. and Rollefstad, S. and Heslinga, M. and McInnes, I. B. and Peters, M. J L and Kvien, T. K. and Dougados, M. and Radner, H. and Atzeni, F. and Primdahl, J. and Södergren, A. and Jonsson, S. Wallberg and van Rompay, J. and Zabalan, C. and Pedersen, T. R. and Jacobsson, Lennart and de Vlam, K. and Gonzalez-Gay, M. A. and Semb, A. G. and Kitas, G. D. and Smulders, Y. M. and Szekanecz, Z. and Sattar, N. and Symmons, D. P M and Nurmohamed, M. T.}},
issn = {{0003-4967}},
language = {{eng}},
number = {{1}},
pages = {{17--28}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update}},
url = {{http://dx.doi.org/10.1136/annrheumdis-2016-209775}},
doi = {{10.1136/annrheumdis-2016-209775}},
volume = {{76}},
year = {{2017}},
}